HTF Market Intelligence released a new research report of 77 pages on title ‘Hepatitis D – Pipeline Review, H2 2016 ‘ with detailed analysis, forecast and strategies.
The latest Pharmaceutical and Healthcare disease pipeline guide Hepatitis D – Pipeline Review, H2 2016, provides an overview of the Hepatitis D (Infectious Disease) pipeline landscape.
Hepatitis D, also known as the delta virus, is an infection that causes liver to swell. It is caused by the hepatitis D virus (HDV). Symptoms include yellowing of skin and eyes, joint pain, abdominal pains, vomiting, loss of appetite and fatigue. Risk factors include receiving many blood transfusions, abusing intravenous (IV) or injection drugs and being infected while pregnant.
Request a sample report @ https://www.htfmarketreport.com/sample-report/138745-hepatitis-d-pipeline-review-3
The Pharmaceutical and Healthcare latest pipeline guide Hepatitis D – Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Hepatitis D (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Hepatitis D (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Hepatitis D and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Preclinical and Discovery stages are 1, 5, 4 and 2 respectively for Similarly, the Universities portfolio in Discovery stages comprises 1 molecules, respectively for Hepatitis D.
Hepatitis D (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from The proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Buy this report @ https://www.htfmarketreport.com/buy-now?format=1&report=138745
Table of Contents
Table of Contents 2
List of Tables 5
List of Figures 5
Global Markets Direct Report Coverage 6
Hepatitis D Overview 7
Therapeutics Development 8
Pipeline Products for Hepatitis D – Overview 8
Pipeline Products for Hepatitis D – Comparative Analysis 9
Hepatitis D – Therapeutics under Development by Companies 10
Hepatitis D – Therapeutics under Investigation by Universities/Institutes 11
Hepatitis D – Pipeline Products Glance 12
Late Stage Products 12
Clinical Stage Products 13
Early Stage Products 14
Hepatitis D – Products under Development by Companies 15
Hepatitis D – Products under Investigation by Universities/Institutes 16
Hepatitis D – Companies Involved in Therapeutics Development 17
Alnylam Pharmaceuticals, Inc. 17
Arrowhead Pharmaceuticals, Inc. 18
Eiger BioPharmaceuticals, Inc. 19
- Hoffmann-La Roche Ltd. 20
Globeimmune, Inc. 21
REPLICor Inc. 22
Rodos BioTarget GmbH 23
SomaGenics, Inc. 24
Spring Bank Pharmaceuticals, Inc. 25
Hepatitis D – Therapeutics Assessment 26
Assessment by Monotherapy Products 26
Assessment by Target 27……
Read Detailed Table of Content @ https://www.htfmarketreport.com/reports/138745-hepatitis-d-pipeline-review-3
– The pipeline guide provides a snapshot of the global therapeutic landscape of Hepatitis D (Infectious Disease).
– The pipeline guide reviews pipeline therapeutics for Hepatitis D (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
– The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
– The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
– The pipeline guide reviews key companies involved in Hepatitis D (Infectious Disease) therapeutics and enlists all their major and minor projects.
– The pipeline guide evaluates Hepatitis D (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
– The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
– The pipeline guide reviews latest news related to pipeline therapeutics for Hepatitis D (Infectious Disease)
Reasons to buy
– Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
– Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
– Find and recognize significant and varied types of therapeutics under development for Hepatitis D (Infectious Disease).
– Classify potential new clients or partners in the target demographic.
– Develop tactical initiatives by understanding the focus areas of leading companies.
– Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
– Formulate corrective measures for pipeline projects by understanding Hepatitis D (Infectious Disease) pipeline depth and focus of Indication therapeutics.
– Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
– Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Make an enquiry before buying this Report @ https://www.htfmarketreport.com/enquiry-before-buy/138745-hepatitis-d-pipeline-review-3
CRAIG FRANCIS (PR & Marketing Manager)
Ph: +1 (206) 317 1218